Matches in SemOpenAlex for { <https://semopenalex.org/work/W1121746598> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W1121746598 endingPage "296" @default.
- W1121746598 startingPage "296" @default.
- W1121746598 abstract "Proc Amer Assoc Cancer Res, Volume 45, 20041295 Approximately 70% of muscle-invasive bladder cancers express the epidermal growth factor receptor (EGFR) and expression is associated with poor prognosis. Recent evidence suggests that irradiation can stimulate EGFR resulting in activation of intracellular cytoprotective signaling cascades. Thus, inhibition of EGFR function, e.g. using a small molecule tyrosine kinase inhibitor (TKI), may be a means of enhancing the radio-responsiveness of bladder tumors. Six bladder cancer cell lines with variable EGFR expression levels were treated with the EGFR-TKI, gefitinib (‘Iressa’, ZD1839), ionizing radiation (IR) or combined gefitinib/IR. Growth inhibition rates were assessed using both MTT and clonogenic assays. Growth inhibition rates determined with IR alone and combined gefitinib/IR were compared to calculate the dose enhancement ratio (DER) achieved with the use of gefitinib in each cell line. Subsequently, EGFR expression levels in each cell line were determined using Western blotting and related to the previously calculated DER. Treatment with gefitinib and IR alone resulted in dose-dependent growth inhibition in all six cell lines (IC50 gefitinib 0.18-2.48 μM). In all six cell lines assessed using clonogenic assay the combination of gefitinib and IR resulted in significantly greater growth inhibition than treatment with either gefitinib or IR alone (Student’s t-test, p=0.001-0.04; DER 1.19-2.00). The enhancement of growth inhibition achieved using combined gefitinib and IR was significant in five of the six cell lines assessed by MTT assay (Student’s t-test, p=0.001-0.03; DER 1.38-2.08). There was no correlation between EGFR expression levels and DERs (Pearson’s correlation; clonogenic assay, r=0.318, p=0.539; MTT assay, r=0.206, p=0.695). Radiosensitization can be achieved in bladder cancer cell lines by the addition of gefitinib to IR. Repetition of these in vitro findings using an in vivo model (work currently underway) would provide sound justification for translating this work into a clinical trial. ‘Iressa’ is a trademark of the AstraZeneca group of companies." @default.
- W1121746598 created "2016-06-24" @default.
- W1121746598 creator A5018876427 @default.
- W1121746598 creator A5027565255 @default.
- W1121746598 creator A5035738138 @default.
- W1121746598 creator A5067116783 @default.
- W1121746598 creator A5079096357 @default.
- W1121746598 date "2004-04-01" @default.
- W1121746598 modified "2023-09-23" @default.
- W1121746598 title "Inhibition of epidermal growth factor receptor with gefitinib (‘Iressa’, ZD1839) improves the response to ionizing radiation in bladder cancer cell lines" @default.
- W1121746598 hasPublicationYear "2004" @default.
- W1121746598 type Work @default.
- W1121746598 sameAs 1121746598 @default.
- W1121746598 citedByCount "0" @default.
- W1121746598 crossrefType "journal-article" @default.
- W1121746598 hasAuthorship W1121746598A5018876427 @default.
- W1121746598 hasAuthorship W1121746598A5027565255 @default.
- W1121746598 hasAuthorship W1121746598A5035738138 @default.
- W1121746598 hasAuthorship W1121746598A5067116783 @default.
- W1121746598 hasAuthorship W1121746598A5079096357 @default.
- W1121746598 hasConcept C117262875 @default.
- W1121746598 hasConcept C121608353 @default.
- W1121746598 hasConcept C126322002 @default.
- W1121746598 hasConcept C170493617 @default.
- W1121746598 hasConcept C185592680 @default.
- W1121746598 hasConcept C2776362946 @default.
- W1121746598 hasConcept C2777506169 @default.
- W1121746598 hasConcept C2779438470 @default.
- W1121746598 hasConcept C2779707156 @default.
- W1121746598 hasConcept C2780352672 @default.
- W1121746598 hasConcept C2780580887 @default.
- W1121746598 hasConcept C2780783641 @default.
- W1121746598 hasConcept C502942594 @default.
- W1121746598 hasConcept C54355233 @default.
- W1121746598 hasConcept C55493867 @default.
- W1121746598 hasConcept C62112901 @default.
- W1121746598 hasConcept C71924100 @default.
- W1121746598 hasConcept C81885089 @default.
- W1121746598 hasConcept C86803240 @default.
- W1121746598 hasConceptScore W1121746598C117262875 @default.
- W1121746598 hasConceptScore W1121746598C121608353 @default.
- W1121746598 hasConceptScore W1121746598C126322002 @default.
- W1121746598 hasConceptScore W1121746598C170493617 @default.
- W1121746598 hasConceptScore W1121746598C185592680 @default.
- W1121746598 hasConceptScore W1121746598C2776362946 @default.
- W1121746598 hasConceptScore W1121746598C2777506169 @default.
- W1121746598 hasConceptScore W1121746598C2779438470 @default.
- W1121746598 hasConceptScore W1121746598C2779707156 @default.
- W1121746598 hasConceptScore W1121746598C2780352672 @default.
- W1121746598 hasConceptScore W1121746598C2780580887 @default.
- W1121746598 hasConceptScore W1121746598C2780783641 @default.
- W1121746598 hasConceptScore W1121746598C502942594 @default.
- W1121746598 hasConceptScore W1121746598C54355233 @default.
- W1121746598 hasConceptScore W1121746598C55493867 @default.
- W1121746598 hasConceptScore W1121746598C62112901 @default.
- W1121746598 hasConceptScore W1121746598C71924100 @default.
- W1121746598 hasConceptScore W1121746598C81885089 @default.
- W1121746598 hasConceptScore W1121746598C86803240 @default.
- W1121746598 hasLocation W11217465981 @default.
- W1121746598 hasOpenAccess W1121746598 @default.
- W1121746598 hasPrimaryLocation W11217465981 @default.
- W1121746598 hasRelatedWork W1600217905 @default.
- W1121746598 hasRelatedWork W2023278402 @default.
- W1121746598 hasRelatedWork W2028288529 @default.
- W1121746598 hasRelatedWork W2053337970 @default.
- W1121746598 hasRelatedWork W2107956424 @default.
- W1121746598 hasRelatedWork W2217199507 @default.
- W1121746598 hasRelatedWork W2314340806 @default.
- W1121746598 hasRelatedWork W2351819250 @default.
- W1121746598 hasRelatedWork W2362294174 @default.
- W1121746598 hasRelatedWork W2374945974 @default.
- W1121746598 hasRelatedWork W2385362989 @default.
- W1121746598 hasRelatedWork W2387047829 @default.
- W1121746598 hasRelatedWork W2391744803 @default.
- W1121746598 hasRelatedWork W2411173500 @default.
- W1121746598 hasRelatedWork W2585501848 @default.
- W1121746598 hasRelatedWork W2998667806 @default.
- W1121746598 hasRelatedWork W3029287291 @default.
- W1121746598 hasRelatedWork W3032708770 @default.
- W1121746598 hasRelatedWork W3144149098 @default.
- W1121746598 hasRelatedWork W2337275110 @default.
- W1121746598 hasVolume "64" @default.
- W1121746598 isParatext "false" @default.
- W1121746598 isRetracted "false" @default.
- W1121746598 magId "1121746598" @default.
- W1121746598 workType "article" @default.